BRIEF published on 09/24/2024 at 23:05, 1 year 6 months ago Theralase clôture un placement privé sans intermédiaire et émet des options sur actions Placement Privé Sans Intermédiaire Technologies Théralase Options Sur Actions Financement De La Recherche Clinique Étude Sur Le Cancer De La Vessie
BRIEF published on 09/24/2024 at 23:05, 1 year 6 months ago Theralase Closes Non-Brokered Private Placement and Issues Stock Options Stock Options Non-brokered Private Placement Theralase Technologies Clinical Research Funding Bladder Cancer Study
PRESS RELEASE published on 09/24/2024 at 23:00, 1 year 6 months ago Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options Theralase Technologies Inc. successfully closes Non-Brokered Private Placement offering of units for cancer research and development Private Placement Pharmaceutical Company Theralase Technologies Inc. Clinical Study Cancer Research
BRIEF published on 09/19/2024 at 23:10, 1 year 6 months ago Theralase® prolonge ses mandats Extension Bourse De Croissance TSX Technologies Théralase Bons De Souscription D'actions Développement Pharmaceutique
BRIEF published on 09/19/2024 at 23:10, 1 year 6 months ago Theralase® Extends Warrants Share Purchase Warrants TSXV Extension Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 09/19/2024 at 23:05, 1 year 6 months ago Theralase(R) Extends Warrants Theralase Technologies Inc. plans to extend expiry date of 10,000,000 share purchase warrants from Sept 22, 2024, to Sept 22, 2027. Warrants issued in 2022 at $0.35/share. TSXV approval pending TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 09/03/2024 at 13:05, 1 year 6 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Ruvidar Antiviral Drug HSV-1 Acyclovir
BRIEF published on 09/03/2024 at 13:05, 1 year 6 months ago Ruvidar(TM) s'avère plus efficace que l'acyclovir dans la destruction du virus de l'herpès simplex Theralase Ruvidar Médicament Antiviral HSV-1 Acyclovir
PRESS RELEASE published on 09/03/2024 at 13:00, 1 year 6 months ago Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus Theralase Technologies Inc. announces preclinical superiority of Ruvidar TM in destroying HSV-1 virus, seeking partnerships for commercial development Theralase Technologies Inc. Preclinical Study Partnerships Ruvidar TM HSV-1 Virus
BRIEF published on 08/28/2024 at 13:05, 1 year 7 months ago Rutherrin® augmente l'efficacité de la chimiothérapie contre le cancer du poumon Theralase® Technologies Inc. Chimiothérapie CPNPC Rutherrine® Cisplatine
Published on 04/01/2026 at 04:06, 2 hours 52 minutes ago Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2025
Published on 04/01/2026 at 03:57, 3 hours 1 minute ago NXT Energy Solutions Announces 2025 Year-End Results
Published on 04/01/2026 at 03:10, 3 hours 48 minutes ago Jaguar Mining Reports Updated Significant 49% Increase in Mineral Reserves at Pilar Mine, Reinforcing Long Term Growth Strategy
Published on 04/01/2026 at 01:40, 5 hours 18 minutes ago Thunder Rock Capital Serves as Exclusive Financial Advisor in Crown Reserve Acquisition Corp. I's Proposed $1.0 Billion Business Combination with Carvix, Inc.
Published on 04/01/2026 at 06:30, 28 minutes ago BYDFi Marks 6th Anniversary with Month-Long Celebration, Built for Reliability
Published on 04/01/2026 at 06:30, 28 minutes ago Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports
Published on 04/01/2026 at 06:00, 58 minutes ago Medacta selected as partner for groundbreaking international research project
Published on 04/01/2026 at 00:15, 6 hours 43 minutes ago Mesabi Metallics Secures $520 Million from Breakwall Capital - Advances towards Q3 2026 start of New American Iron Ore Mine
Published on 03/31/2026 at 23:05, 7 hours 53 minutes ago DeFi Technologies Announces Preliminary Unaudited Full Year 2025 Financial Results with Record Revenue of $99.1 Million and Record Net Income of $62.7 Million; Appoints New Independent Chair of the Audit Committee
Published on 03/31/2026 at 20:08, 10 hours 50 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 11 hours 52 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 11 hours 52 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
Published on 03/31/2026 at 19:00, 11 hours 58 minutes ago COGRA : Transfert du contrat de liquidité chez TSAF
Published on 03/31/2026 at 18:34, 12 hours 23 minutes ago Damartex / Transfert du contrat de liquidité auprès du Crédit Industriel et Commercial
